Skip to main content
Top

08-06-2024 | Rifaximin | IM - ORIGINAL

Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners

Authors: Luigi Gatta, Massimo Bellini, Carmelo Scarpignato, Walter Marrocco, Alberto Chiriatti, Antonio Grosso, Christian Lambiase, Paolo Usai-Satta, Roberto Vassallo, Pierluigi Bartoletti, Fabio Monica, Raffaele Manta, Silvestro Scotti, Marco Soncini, on behalf of the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Federation of General Practitioners (FIMMG)

Published in: Internal and Emergency Medicine

Login to get access

Abstract

The management of patients with diverticular disease remains challenging. The aim of this national survey was to assess how gastroenterologists and general practitioners use rifaximin to manage diverticulosis and diverticular disease. Members of the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Federation of General Practitioners (FIMMG) were invited to complete a 39-item online survey concerning the use of rifaximin in five clinical settings: (1) diverticulosis; (2) reducing symptoms in symptomatic uncomplicated diverticular disease; (3) reducing the occurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease (primary prevention); (4) reducing the recurrence of diverticulitis in patients with previous attacks of diverticulitis (secondary prevention); (5) treatment of uncomplicated acute diverticulitis. A total of 1094 physicians completed the survey. Overall, 25.1%, 83.5%, 68%, 74.2%, and 63% of physicians prescribed rifaximin for the clinical settings 1, 2, 3, 4, and 5, respectively. In each clinical setting, the dosage of rifaximin most frequently used was 800 mg/day, the most common duration of therapy was 7 days, and the cyclic administration of treatment (expressed in months) most frequently used was > 24 months. These results highlight that a reappraisal of the use of rifaximin in patients with diverticulosis and diverticular disease is required to reduce the gap between the evidence available and the daily clinical practice, optimizing also the use of healthcare resources.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zullo A, Gatta L, Vassallo R, Francesco V, Manta R, Monica F et al (2019) Paradigm shift: the Copernican revolution in diverticular disease. Ann Gastroenterol 32(6):541–553PubMedPubMedCentral Zullo A, Gatta L, Vassallo R, Francesco V, Manta R, Monica F et al (2019) Paradigm shift: the Copernican revolution in diverticular disease. Ann Gastroenterol 32(6):541–553PubMedPubMedCentral
3.
go back to reference Tursi A, Brandimarte G, Di Mario F, Lanas A, Scarpignato C, Bafutto M et al (2019) International consensus on diverticulosis and diverticular disease: statements from the 3rd international symposium on diverticular disease. J Gastrointest Liver Dis 28(suppl. 4):57–66 Tursi A, Brandimarte G, Di Mario F, Lanas A, Scarpignato C, Bafutto M et al (2019) International consensus on diverticulosis and diverticular disease: statements from the 3rd international symposium on diverticular disease. J Gastrointest Liver Dis 28(suppl. 4):57–66
4.
go back to reference Cuomo R, Barbara G, Annibale B (2017) Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig Liv Dis 49(6):595–603CrossRef Cuomo R, Barbara G, Annibale B (2017) Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig Liv Dis 49(6):595–603CrossRef
6.
go back to reference Bharucha AE, Parthasarathy G, Ditah I, Fletcher JG, Ewelukwa O, Pendlimari R et al (2015) Temporal trends in the incidence and natural history of diverticulitis: a population-based study. Am J Gastroenterol 110(11):1589–1596PubMedPubMedCentralCrossRef Bharucha AE, Parthasarathy G, Ditah I, Fletcher JG, Ewelukwa O, Pendlimari R et al (2015) Temporal trends in the incidence and natural history of diverticulitis: a population-based study. Am J Gastroenterol 110(11):1589–1596PubMedPubMedCentralCrossRef
7.
go back to reference Binda GA, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R et al (2018) Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Tech Coloproctol 22(8):597–604PubMedCrossRef Binda GA, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R et al (2018) Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Tech Coloproctol 22(8):597–604PubMedCrossRef
9.
go back to reference Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL et al (2019) Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156(1):254-272.e211PubMedCrossRef Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL et al (2019) Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156(1):254-272.e211PubMedCrossRef
10.
go back to reference Santacroce G, Lenti MV, Abruzzese GM, Alunno G, Di Terlizzi F, Frenna C et al (2024) Diagnostic delay in symptomatic uncomplicated diverticular disease: an Italian tertiary referral centre study. Intern Emerg Med 19(1):99–106PubMedCrossRef Santacroce G, Lenti MV, Abruzzese GM, Alunno G, Di Terlizzi F, Frenna C et al (2024) Diagnostic delay in symptomatic uncomplicated diverticular disease: an Italian tertiary referral centre study. Intern Emerg Med 19(1):99–106PubMedCrossRef
11.
go back to reference Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA et al (2014) Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur Gastroenterol J 2(5):413–442CrossRef Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA et al (2014) Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur Gastroenterol J 2(5):413–442CrossRef
12.
go back to reference Binda GA, Cuomo R, Laghi A, Nascimbeni R, Serventi A, Bellini D et al (2015) Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Tech Coloproctol 19(10):615–626PubMedCrossRef Binda GA, Cuomo R, Laghi A, Nascimbeni R, Serventi A, Bellini D et al (2015) Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Tech Coloproctol 19(10):615–626PubMedCrossRef
13.
go back to reference Strate LL, Gralnek IM (2016) ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 111(4):459–474PubMedPubMedCentralCrossRef Strate LL, Gralnek IM (2016) ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 111(4):459–474PubMedPubMedCentralCrossRef
14.
go back to reference Schultz JK, Azhar N, Binda GA, Barbara G, Biondo S, Boermeester MA et al (2020) European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. Colorectal Dis 22(Suppl 2):5–28PubMedCrossRef Schultz JK, Azhar N, Binda GA, Barbara G, Biondo S, Boermeester MA et al (2020) European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. Colorectal Dis 22(Suppl 2):5–28PubMedCrossRef
15.
go back to reference Peery AF, Shaukat A, Strate LL (2021) AGA clinical practice update on medical management of colonic diverticulitis: expert review. Gastroenterology 160(3):906-911.e901PubMedCrossRef Peery AF, Shaukat A, Strate LL (2021) AGA clinical practice update on medical management of colonic diverticulitis: expert review. Gastroenterology 160(3):906-911.e901PubMedCrossRef
16.
go back to reference Scarpignato C, Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51(suppl. 1):36–66PubMedCrossRef Scarpignato C, Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51(suppl. 1):36–66PubMedCrossRef
17.
go back to reference Piccin A, Gulotta M, di Bella S, Martingano P, Croce LS, Giuffre M (2023) Diverticular disease and rifaximin: an evidence-based review. Antibiotics (Basel) 12(3):443PubMedCrossRef Piccin A, Gulotta M, di Bella S, Martingano P, Croce LS, Giuffre M (2023) Diverticular disease and rifaximin: an evidence-based review. Antibiotics (Basel) 12(3):443PubMedCrossRef
18.
go back to reference Gatta L, Scarpignato C (2017) Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 45(5):604–616PubMedPubMedCentralCrossRef Gatta L, Scarpignato C (2017) Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 45(5):604–616PubMedPubMedCentralCrossRef
19.
go back to reference Newcombe RG, Altman DG (2000) Proportions and their difference. In: Altman DG, Machin D, Bryant T, Gardner M (eds) Statistics with confidence, 2nd edn. BMJ Books, London Newcombe RG, Altman DG (2000) Proportions and their difference. In: Altman DG, Machin D, Bryant T, Gardner M (eds) Statistics with confidence, 2nd edn. BMJ Books, London
20.
go back to reference Kleinbaum DG, Klein M (2010) SpringerLink: Logistic regression: a self-learning text. Springer, New York, New York, NY Kleinbaum DG, Klein M (2010) SpringerLink: Logistic regression: a self-learning text. Springer, New York, New York, NY
21.
go back to reference Kang JY, Hoare J, Tinto A, Subramanian S, Ellis C, Majeed A et al (2003) Diverticular disease of the colon: on the rise—a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther 17(9):1189–1195PubMedCrossRef Kang JY, Hoare J, Tinto A, Subramanian S, Ellis C, Majeed A et al (2003) Diverticular disease of the colon: on the rise—a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther 17(9):1189–1195PubMedCrossRef
22.
go back to reference Paterson HM, Arnott ID, Nicholls RJ, Clark D, Bauer J, Bridger PC et al (2015) Diverticular disease in Scotland: 2000–2010. Colorectal Dis 17(4):329–334PubMedCrossRef Paterson HM, Arnott ID, Nicholls RJ, Clark D, Bauer J, Bridger PC et al (2015) Diverticular disease in Scotland: 2000–2010. Colorectal Dis 17(4):329–334PubMedCrossRef
23.
go back to reference Jeyarajah S, Faiz O, Bottle A, Aylin P, Bjarnason I, Tekkis PP et al (2009) Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. Aliment Pharmacol Ther 30(11–12):1171–1182PubMedCrossRef Jeyarajah S, Faiz O, Bottle A, Aylin P, Bjarnason I, Tekkis PP et al (2009) Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. Aliment Pharmacol Ther 30(11–12):1171–1182PubMedCrossRef
24.
go back to reference Amato A, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R et al (2020) Hospital admission for complicated diverticulitis is increasing in Italy, especially in younger patients: a national database study. Tech Coloproctol 24(3):237–245PubMedCrossRef Amato A, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R et al (2020) Hospital admission for complicated diverticulitis is increasing in Italy, especially in younger patients: a national database study. Tech Coloproctol 24(3):237–245PubMedCrossRef
25.
go back to reference Alexandersson BT, Stefansson T (2020) Incidence and recurrence rate of sigmoid diverticulitis in patients requiring admission to hospital in Iceland from 1985 to 2014: nationwide population-based register study. BJS Open 4(6):1217–1226PubMedPubMedCentralCrossRef Alexandersson BT, Stefansson T (2020) Incidence and recurrence rate of sigmoid diverticulitis in patients requiring admission to hospital in Iceland from 1985 to 2014: nationwide population-based register study. BJS Open 4(6):1217–1226PubMedPubMedCentralCrossRef
26.
go back to reference Spiller R (2012) Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 30(1):64–69PubMedCrossRef Spiller R (2012) Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 30(1):64–69PubMedCrossRef
27.
go back to reference Alamo RZ, Quigley EMM (2019) Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. Curr Opin Gastroenterol 35(1):27–33PubMedCrossRef Alamo RZ, Quigley EMM (2019) Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. Curr Opin Gastroenterol 35(1):27–33PubMedCrossRef
28.
go back to reference Andersen JC, Bundgaard L, Elbrønd H, Laurberg S, Walker LR, Støvring J (2012) Danish national guidelines for treatment of diverticular disease. Dan Med J 59(5):C4453PubMed Andersen JC, Bundgaard L, Elbrønd H, Laurberg S, Walker LR, Støvring J (2012) Danish national guidelines for treatment of diverticular disease. Dan Med J 59(5):C4453PubMed
29.
go back to reference Pietrzak A, Bartnik W, Szczepkowski M, K rokowicz P, Dziki A, Regulła J, et al (2015) Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis (2015). Pol Przegl Chir 87(4):203–220PubMedCrossRef Pietrzak A, Bartnik W, Szczepkowski M, K rokowicz P, Dziki A, Regulła J, et al (2015) Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis (2015). Pol Przegl Chir 87(4):203–220PubMedCrossRef
30.
go back to reference Trifan A, Gheorghe C, Sabo CM, Diculescu M, Nedelcu L, Singeap AM et al (2018) Diagnosis and treatment of colonic diverticular disease: position paper of the Romanian society of gastroenterology and hepatology. J Gastrointest Liver Dis 27(4):449–457CrossRef Trifan A, Gheorghe C, Sabo CM, Diculescu M, Nedelcu L, Singeap AM et al (2018) Diagnosis and treatment of colonic diverticular disease: position paper of the Romanian society of gastroenterology and hepatology. J Gastrointest Liver Dis 27(4):449–457CrossRef
31.
go back to reference Raña-Garibay R, Salgado-Nesme N, Carmona-Sánchez R, Remes-Troche JM, Aguilera-Carrera J, Alonso-Sánchez L et al (2019) The Mexican consensus on the diagnosis and treatment of diverticular disease of the colon. Rev Gastroenterol Mex (Eng Ed) 84(2):220–240 Raña-Garibay R, Salgado-Nesme N, Carmona-Sánchez R, Remes-Troche JM, Aguilera-Carrera J, Alonso-Sánchez L et al (2019) The Mexican consensus on the diagnosis and treatment of diverticular disease of the colon. Rev Gastroenterol Mex (Eng Ed) 84(2):220–240
33.
go back to reference Kruis W, Germer CT, Bohm S, Dumoulin FL, Frieling T, Hampe J et al (2022) German guideline diverticular disease/diverticulitis: part II—conservative, interventional and surgical management. United Eur Gastroenterol J 10(9):940–957CrossRef Kruis W, Germer CT, Bohm S, Dumoulin FL, Frieling T, Hampe J et al (2022) German guideline diverticular disease/diverticulitis: part II—conservative, interventional and surgical management. United Eur Gastroenterol J 10(9):940–957CrossRef
34.
35.
go back to reference Papi C, Ciaco A, Koch M, Capurso L (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon: a pilot multicentre open trial—diverticular disease study group. Ital J Gastroenterol 24(8):452–456PubMed Papi C, Ciaco A, Koch M, Capurso L (1992) Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon: a pilot multicentre open trial—diverticular disease study group. Ital J Gastroenterol 24(8):452–456PubMed
36.
go back to reference Papi C, Ciaco A, Koch M, Capurso L (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon: a multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9(1):33–39PubMedCrossRef Papi C, Ciaco A, Koch M, Capurso L (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon: a multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9(1):33–39PubMedCrossRef
37.
go back to reference Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18(1):55–62PubMedCrossRef Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M et al (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18(1):55–62PubMedCrossRef
38.
go back to reference Lanas A, Ponce J, Bignamini A, Mearin F (2013) One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig Liver Dis 45(2):104–109PubMedCrossRef Lanas A, Ponce J, Bignamini A, Mearin F (2013) One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig Liver Dis 45(2):104–109PubMedCrossRef
39.
go back to reference Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A et al (2017) Retrospective comparison of long-term 10-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. Eur Rev Med Pharmacol Sci 21(6):1397–1404PubMed Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A et al (2017) Retrospective comparison of long-term 10-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. Eur Rev Med Pharmacol Sci 21(6):1397–1404PubMed
40.
go back to reference Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34(7):510–515PubMedCrossRef Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34(7):510–515PubMedCrossRef
41.
go back to reference Brandimarte G, Tursi A (2004) Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 10(5):Pi70-73PubMed Brandimarte G, Tursi A (2004) Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 10(5):Pi70-73PubMed
42.
go back to reference Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K et al (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11(12):1614–1619PubMedPubMedCentralCrossRef Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K et al (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11(12):1614–1619PubMedPubMedCentralCrossRef
43.
go back to reference Lahat A, Necula D, Yavzori M, Picard O, Halperin S, Eliakim R et al (2019) Prolonged recurrent abdominal pain is associated with ongoing underlying mucosal inflammation in patients who had an episode of acute complicated diverticulitis. J Clin Gastroenterol 53(5):E178–E185PubMedCrossRef Lahat A, Necula D, Yavzori M, Picard O, Halperin S, Eliakim R et al (2019) Prolonged recurrent abdominal pain is associated with ongoing underlying mucosal inflammation in patients who had an episode of acute complicated diverticulitis. J Clin Gastroenterol 53(5):E178–E185PubMedCrossRef
44.
go back to reference Strate LL, Morris AM (2019) Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology 156(5):1282–1298PubMedCrossRef Strate LL, Morris AM (2019) Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology 156(5):1282–1298PubMedCrossRef
45.
go back to reference Shahedi K, Fuller G, Bolus R, Cohen E, Vu M, Shah R et al (2013) Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol 11(12):1609–1613PubMedPubMedCentralCrossRef Shahedi K, Fuller G, Bolus R, Cohen E, Vu M, Shah R et al (2013) Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol 11(12):1609–1613PubMedPubMedCentralCrossRef
46.
go back to reference Di Pierro F, Pane M (2021) Bifidobacterium longum W11: uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN 42:15–21PubMedCrossRef Di Pierro F, Pane M (2021) Bifidobacterium longum W11: uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN 42:15–21PubMedCrossRef
47.
go back to reference Graziano T, Amoruso A, Nicola S, Deidda F, Allesina S, Pane M et al (2016) The possible innovative use of Bifidobacterium longum w11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol 50(Suppl 2):S153–S156PubMedCrossRef Graziano T, Amoruso A, Nicola S, Deidda F, Allesina S, Pane M et al (2016) The possible innovative use of Bifidobacterium longum w11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol 50(Suppl 2):S153–S156PubMedCrossRef
48.
go back to reference Di Pierro F, Bertuccioli A, Pane M, Ivaldi L (2019) Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin. Minerva Gastroenterol Dietol 65(4):259–264PubMed Di Pierro F, Bertuccioli A, Pane M, Ivaldi L (2019) Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin. Minerva Gastroenterol Dietol 65(4):259–264PubMed
49.
go back to reference Lahner E, Annibale B (2016) Probiotics and diverticular disease: evidence-based? J Clin Gastroenterol 50(Suppl 2):S159–S160PubMedCrossRef Lahner E, Annibale B (2016) Probiotics and diverticular disease: evidence-based? J Clin Gastroenterol 50(Suppl 2):S159–S160PubMedCrossRef
50.
go back to reference Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM (2017) Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes 8(6):521–543PubMedPubMedCentralCrossRef Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM (2017) Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes 8(6):521–543PubMedPubMedCentralCrossRef
51.
go back to reference Ojetti V, Petruzziello C, Cardone S, Saviano L, Migneco A, Santarelli L et al (2018) The use of probiotics in different phases of diverticular disease. Rev Recent Clin Trials 13(2):89–96PubMedCrossRef Ojetti V, Petruzziello C, Cardone S, Saviano L, Migneco A, Santarelli L et al (2018) The use of probiotics in different phases of diverticular disease. Rev Recent Clin Trials 13(2):89–96PubMedCrossRef
52.
go back to reference Scarpignato C, Bertele A, Tursi A (2016) Probiotics for the treatment of symptomatic uncomplicated diverticular disease: rationale and current evidence. J Clin Gastroenterol 50:S70–S73PubMedCrossRef Scarpignato C, Bertele A, Tursi A (2016) Probiotics for the treatment of symptomatic uncomplicated diverticular disease: rationale and current evidence. J Clin Gastroenterol 50:S70–S73PubMedCrossRef
53.
go back to reference Aday LA, Cornelius LJ (2006) Designing and conducting health surveys: a comprehensive guide, vol. 3, 3rd edn. Jossey-Bass, San Francisco Aday LA, Cornelius LJ (2006) Designing and conducting health surveys: a comprehensive guide, vol. 3, 3rd edn. Jossey-Bass, San Francisco
54.
go back to reference Johnson TP (2015) Handbook of health survey methods, 1st edn. Wiley, Hoboken, New Jersey Johnson TP (2015) Handbook of health survey methods, 1st edn. Wiley, Hoboken, New Jersey
56.
go back to reference Menees SB, Guentner A, Chey SW, Saad R, Chey WD (2015) How do US gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation? Am J Gastroenterol 110(11):1516–1525PubMedCrossRef Menees SB, Guentner A, Chey SW, Saad R, Chey WD (2015) How do US gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation? Am J Gastroenterol 110(11):1516–1525PubMedCrossRef
57.
go back to reference Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ et al (2020) Physicians’ perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey. Am J Gastroenterol 115(5):689–696PubMedPubMedCentralCrossRef Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ et al (2020) Physicians’ perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey. Am J Gastroenterol 115(5):689–696PubMedPubMedCentralCrossRef
58.
go back to reference Calini G, Abd El Aziz MA, Paolini L, Abdalla S, Rottoli M, Mari G et al (2023) Symptomatic uncomplicated diverticular disease (SUDD): practical guidance and challenges for clinical management. Clin Exp Gastroenterol 16:29–43PubMedPubMedCentralCrossRef Calini G, Abd El Aziz MA, Paolini L, Abdalla S, Rottoli M, Mari G et al (2023) Symptomatic uncomplicated diverticular disease (SUDD): practical guidance and challenges for clinical management. Clin Exp Gastroenterol 16:29–43PubMedPubMedCentralCrossRef
59.
go back to reference Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394PubMedCrossRef Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394PubMedCrossRef
Metadata
Title
Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners
Authors
Luigi Gatta
Massimo Bellini
Carmelo Scarpignato
Walter Marrocco
Alberto Chiriatti
Antonio Grosso
Christian Lambiase
Paolo Usai-Satta
Roberto Vassallo
Pierluigi Bartoletti
Fabio Monica
Raffaele Manta
Silvestro Scotti
Marco Soncini
on behalf of the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Federation of General Practitioners (FIMMG)
Publication date
08-06-2024
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-024-03669-6
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare